KR20220145861A - 암 및 종양을 치료하기 위한 조성물 및 방법 - Google Patents

암 및 종양을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20220145861A
KR20220145861A KR1020227032630A KR20227032630A KR20220145861A KR 20220145861 A KR20220145861 A KR 20220145861A KR 1020227032630 A KR1020227032630 A KR 1020227032630A KR 20227032630 A KR20227032630 A KR 20227032630A KR 20220145861 A KR20220145861 A KR 20220145861A
Authority
KR
South Korea
Prior art keywords
day
body weight
tumor
cancer
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227032630A
Other languages
English (en)
Korean (ko)
Inventor
강신욱
김경순
성지혜
Original Assignee
오블라토 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오블라토 인코포레이티드 filed Critical 오블라토 인코포레이티드
Publication of KR20220145861A publication Critical patent/KR20220145861A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227032630A 2020-02-24 2021-02-24 암 및 종양을 치료하기 위한 조성물 및 방법 Pending KR20220145861A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062980645P 2020-02-24 2020-02-24
US62/980,645 2020-02-24
PCT/US2021/019457 WO2021173702A1 (en) 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor

Publications (1)

Publication Number Publication Date
KR20220145861A true KR20220145861A (ko) 2022-10-31

Family

ID=77490220

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227032630A Pending KR20220145861A (ko) 2020-02-24 2021-02-24 암 및 종양을 치료하기 위한 조성물 및 방법

Country Status (8)

Country Link
US (1) US20230092005A1 (enExample)
EP (1) EP4110315A4 (enExample)
JP (1) JP2023514742A (enExample)
KR (1) KR20220145861A (enExample)
CN (1) CN115151250A (enExample)
AU (1) AU2021228654A1 (enExample)
CA (1) CA3168980A1 (enExample)
WO (1) WO2021173702A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
WO2009102808A2 (en) * 2008-02-12 2009-08-20 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
AU2009288057B2 (en) * 2008-09-02 2014-07-03 Oklahoma Medical Research Foundation 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
WO2012106313A2 (en) * 2011-01-31 2012-08-09 Oklahoma Medical Research Foundation Ubiquitin interacting motif peptides as cancer therapeutics
EP3570826A4 (en) * 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
KR101905864B1 (ko) * 2017-03-20 2018-10-08 아주대학교산학협력단 Sulf2 유전자를 이용한 소라페닙 치료에 대한 감수성 예측방법 및 sulf2 저해제를 포함하는 암 치료용 조성물
ES3063479T3 (en) * 2017-09-20 2026-04-16 Oklahoma Med Res Found Treatment of drug resistant gliomas
EP3787750A1 (en) * 2018-05-03 2021-03-10 Hough Ear Institute Methods for reducing accumulated pathologic tau protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Guanjai Dai et al., Myricanol Induces Apoptotic Cell Death and Anti-Tumor Activity in Non-Small Cell Lung Carcinoma in Vivo, International Journal of Molecular Sciences. 2015 Jan.; 16(2): 2717-2731.
Rhyu JJ et al., Dual effects of human adipose tissue-derived mesenchymal stem cells in human lung adenocarcinoma A549 xenografts and colorectal adenocarcinoma HT-29 xenografts in mice, Oncology Reports. 2015 Oct.; 34(4): 1733-1744.
Towner, et al., OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth, Translational Oncology, 2019 Feb.; 12(2): 320-335.
Towner, et al., Regression of glioma tumor growth in F98 and U87 rat glioma models by the Nitrone OKN-007, Neuro Oncology 2013 Jan.; 15(3): 330-340.

Also Published As

Publication number Publication date
CN115151250A (zh) 2022-10-04
US20230092005A1 (en) 2023-03-23
WO2021173702A1 (en) 2021-09-02
JP2023514742A (ja) 2023-04-07
EP4110315A1 (en) 2023-01-04
AU2021228654A1 (en) 2022-10-13
CA3168980A1 (en) 2021-09-02
EP4110315A4 (en) 2024-03-06
WO2021173702A8 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
Melisi et al. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
Wang et al. Combination of fruquintinib and anti–PD-1 for the treatment of colorectal cancer
US20230093147A1 (en) Methods and compositions relating to improved combination therapies
CN109069426B (zh) 治疗癌症的方法
JP2021138704A (ja) 神経膠芽腫の治療のための併用療法
US8883737B2 (en) Methods of treating cancer
US20230181565A1 (en) Crenolanib combination therapy
JP7579636B2 (ja) 膵がん治療のための組み合わせ治療薬
AU2015360761B2 (en) Treatment of breast cancer with liposomal irinotecan
Gao et al. Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer
Kojima et al. Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors
US20200071415A1 (en) Combination therapy for pancreatic cancer
Minami et al. Phase I study of LFA102 in patients with advanced breast cancer or castration-resistant prostate cancer
Solomon et al. Avelumab in combination with lorlatinib or crizotinib in patients with previously treated advanced NSCLC: phase 1b/2 results from the JAVELIN lung 101 trial
KR20240158972A (ko) 소세포 폐암의 치료 방법
Shin et al. FOXM1 inhibitor-loaded nanoliposomes for enhanced immunotherapy against cancer
Kawano et al. Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma
KR20220145861A (ko) 암 및 종양을 치료하기 위한 조성물 및 방법
Balza et al. Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models
WO2021031998A1 (en) Recombinant polypeptides and uses thereof
US12544366B2 (en) Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms
US11484591B2 (en) Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
Zhu et al. Synergistic Activation of Immunogenic Cell Death and the cGAS–STING Pathway by Engineered Zinc/Manganese‐Based Metal–Organic Framework Nanoplatforms for Colon Cancer Immunotherapy
JP6898862B2 (ja) 放射線増感剤として作用する多剤複合薬
US20230058726A1 (en) Chemoprevention using controlled- release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902